Scientific Advisory Board

Dr. Asim Dasgupta, Ph.D Chemistry/Biochemistry,
Virologist and molecular Biologist serving on UCLA Faculty since 1981. Postdoctoral fellow at MIT working with Nobel Prize winner Dr. David Baltimore with focus on RNA Virus replication. Recipient of American Cancer Society Faculty Research Award and NIH Career Development Award.

Dr. Bart Chapman, MD, MBA, FAAO.
A board certified physician with over 30 successful years in the biopharmaceutical industry who has been involved in approved NDAs and PMAs and directing clinical trials through all phases.

He has worked for many years with numerous oncology therapeutics especially in the realm of mono clonal antibodies.

His role has varied from developing Phase I-IV protocols and implementing them to designing and implementing MOPS which have included integrating protocol design and phase I- IV implementation with the launch and marketing of approved products.

As a pharmacovigilence medical director he has been responsible for the following:

• Developing g strategies for identifying product safety concerns
• Standardized AE/SAE formats/AERS
• Impact assessments
• Communication strategies regarding safety
• Communications and responses to regulatory authorities in regards to safety issues
• Mitigation strategies
• Phase I-IV safety issues

Dr. Carol Hunter, Ph.D.
In-Patient Pharmacy Manager at McKay-Dee Hospital. Ms Hunter received her doctorate of pharmacy degree from the University of Florida where she graduated with honors. She has worked for Intermountain Healthcare for 31 years.

Dr. Michael Rosenblum, Ph.D.
Professor of Medicine at the M.D. Anderson Cancer Center. Working in pharmacology of biological agents, particularly proteins, which are capable of targeting selected cells and developing tumor cell–targeted cytotoxic agents. Additionally, researching tumor cell–signaling events and employing signaling strategies to achieve therapeutic goals.

Top